The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. / Starhof, Charlotte; Hejl, Anne-Mette; Heegaard, Niels H H; Carlsen, Anting L; Burton, Mark; Lilje, Berit; Winge, Kristian.

In: Movement disorders : official journal of the Movement Disorder Society, Vol. 34, No. 2, 02.2019, p. 246-254.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Starhof, C, Hejl, A-M, Heegaard, NHH, Carlsen, AL, Burton, M, Lilje, B & Winge, K 2019, 'The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes', Movement disorders : official journal of the Movement Disorder Society, vol. 34, no. 2, pp. 246-254. https://doi.org/10.1002/mds.27542

APA

Starhof, C., Hejl, A-M., Heegaard, N. H. H., Carlsen, A. L., Burton, M., Lilje, B., & Winge, K. (2019). The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. Movement disorders : official journal of the Movement Disorder Society, 34(2), 246-254. https://doi.org/10.1002/mds.27542

Vancouver

Starhof C, Hejl A-M, Heegaard NHH, Carlsen AL, Burton M, Lilje B et al. The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. Movement disorders : official journal of the Movement Disorder Society. 2019 Feb;34(2):246-254. https://doi.org/10.1002/mds.27542

Author

Starhof, Charlotte ; Hejl, Anne-Mette ; Heegaard, Niels H H ; Carlsen, Anting L ; Burton, Mark ; Lilje, Berit ; Winge, Kristian. / The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. In: Movement disorders : official journal of the Movement Disorder Society. 2019 ; Vol. 34, No. 2. pp. 246-254.

Bibtex

@article{e5897432fb3c4f999ec5c24dc67b0c04,
title = "The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes",
abstract = "BACKGROUND: MicroRNAs are small noncoding RNAs involved in the post-transcriptional regulation of protein synthesis. Extracellular microRNAs are accessible in a stable form in biofluids.OBJECTIVES: The aim was to identify individual microRNAs and/or subsets of microRNAs in CSF with biomarker potential and thus identify specific putative pathophysiological pathways.METHODS: In a two-step exploratory study design of PD, MSA, PSP, and controls, we initially profiled CSF microRNAs in a pilot cohort (n = 40) by screening for 372 microRNAs. Subsequently, we attempted to validate findings in an independent study cohort in CSF (n = 118) and ethylenediaminetetraacetic acid plasma (n = 114). This study cohort encompassed 46 microRNAs, of which 26 were singled out from the pilot cohort, and an additional 20 microRNAs were added based on previous publications. The most accurate diagnostic microRNA classifiers were identified in a multivariable logistic regression model adjusted for age and sex.RESULTS: A set of three microRNAs in CSF discriminated PD and MSA from controls with good diagnostic accuracy by receiver operating characteristics curve evaluation. The microRNAs were for PD versus controls: miR-7-5p, miR-331-5p, and miR-145-5p (area under the curve = 0.88) and MSA versus controls: miR-7-5p, miR-34c-3p, and miR-let-7b-5p (area under the curve = 0.87). The classifier that best distinguished MSA and PD consisted of two microRNAs: miR-9-3p and miR-106b-5p (area under the curve = 0.73). A single microRNA, miR-106b-5p, provided the best discrimination between PD and PSP (area under the curve = 0.85) in the CSF.CONCLUSIONS: Levels of specific trios of CSF-microRNAs discriminate well between α-synucleinopathies (PD and MSA) and controls. The results need to be validated in larger, independent cohorts. {\textcopyright} 2018 International Parkinson and Movement Disorder Society.",
keywords = "Alzheimer Disease/cerebrospinal fluid, Biomarkers/blood, Circulating MicroRNA/cerebrospinal fluid, Cohort Studies, Female, Gene Expression Regulation/genetics, Humans, Male, Parkinson Disease/cerebrospinal fluid, Parkinsonian Disorders/blood",
author = "Charlotte Starhof and Anne-Mette Hejl and Heegaard, {Niels H H} and Carlsen, {Anting L} and Mark Burton and Berit Lilje and Kristian Winge",
note = "{\textcopyright} 2018 International Parkinson and Movement Disorder Society.",
year = "2019",
month = feb,
doi = "10.1002/mds.27542",
language = "English",
volume = "34",
pages = "246--254",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "JohnWiley & Sons, Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes

AU - Starhof, Charlotte

AU - Hejl, Anne-Mette

AU - Heegaard, Niels H H

AU - Carlsen, Anting L

AU - Burton, Mark

AU - Lilje, Berit

AU - Winge, Kristian

N1 - © 2018 International Parkinson and Movement Disorder Society.

PY - 2019/2

Y1 - 2019/2

N2 - BACKGROUND: MicroRNAs are small noncoding RNAs involved in the post-transcriptional regulation of protein synthesis. Extracellular microRNAs are accessible in a stable form in biofluids.OBJECTIVES: The aim was to identify individual microRNAs and/or subsets of microRNAs in CSF with biomarker potential and thus identify specific putative pathophysiological pathways.METHODS: In a two-step exploratory study design of PD, MSA, PSP, and controls, we initially profiled CSF microRNAs in a pilot cohort (n = 40) by screening for 372 microRNAs. Subsequently, we attempted to validate findings in an independent study cohort in CSF (n = 118) and ethylenediaminetetraacetic acid plasma (n = 114). This study cohort encompassed 46 microRNAs, of which 26 were singled out from the pilot cohort, and an additional 20 microRNAs were added based on previous publications. The most accurate diagnostic microRNA classifiers were identified in a multivariable logistic regression model adjusted for age and sex.RESULTS: A set of three microRNAs in CSF discriminated PD and MSA from controls with good diagnostic accuracy by receiver operating characteristics curve evaluation. The microRNAs were for PD versus controls: miR-7-5p, miR-331-5p, and miR-145-5p (area under the curve = 0.88) and MSA versus controls: miR-7-5p, miR-34c-3p, and miR-let-7b-5p (area under the curve = 0.87). The classifier that best distinguished MSA and PD consisted of two microRNAs: miR-9-3p and miR-106b-5p (area under the curve = 0.73). A single microRNA, miR-106b-5p, provided the best discrimination between PD and PSP (area under the curve = 0.85) in the CSF.CONCLUSIONS: Levels of specific trios of CSF-microRNAs discriminate well between α-synucleinopathies (PD and MSA) and controls. The results need to be validated in larger, independent cohorts. © 2018 International Parkinson and Movement Disorder Society.

AB - BACKGROUND: MicroRNAs are small noncoding RNAs involved in the post-transcriptional regulation of protein synthesis. Extracellular microRNAs are accessible in a stable form in biofluids.OBJECTIVES: The aim was to identify individual microRNAs and/or subsets of microRNAs in CSF with biomarker potential and thus identify specific putative pathophysiological pathways.METHODS: In a two-step exploratory study design of PD, MSA, PSP, and controls, we initially profiled CSF microRNAs in a pilot cohort (n = 40) by screening for 372 microRNAs. Subsequently, we attempted to validate findings in an independent study cohort in CSF (n = 118) and ethylenediaminetetraacetic acid plasma (n = 114). This study cohort encompassed 46 microRNAs, of which 26 were singled out from the pilot cohort, and an additional 20 microRNAs were added based on previous publications. The most accurate diagnostic microRNA classifiers were identified in a multivariable logistic regression model adjusted for age and sex.RESULTS: A set of three microRNAs in CSF discriminated PD and MSA from controls with good diagnostic accuracy by receiver operating characteristics curve evaluation. The microRNAs were for PD versus controls: miR-7-5p, miR-331-5p, and miR-145-5p (area under the curve = 0.88) and MSA versus controls: miR-7-5p, miR-34c-3p, and miR-let-7b-5p (area under the curve = 0.87). The classifier that best distinguished MSA and PD consisted of two microRNAs: miR-9-3p and miR-106b-5p (area under the curve = 0.73). A single microRNA, miR-106b-5p, provided the best discrimination between PD and PSP (area under the curve = 0.85) in the CSF.CONCLUSIONS: Levels of specific trios of CSF-microRNAs discriminate well between α-synucleinopathies (PD and MSA) and controls. The results need to be validated in larger, independent cohorts. © 2018 International Parkinson and Movement Disorder Society.

KW - Alzheimer Disease/cerebrospinal fluid

KW - Biomarkers/blood

KW - Circulating MicroRNA/cerebrospinal fluid

KW - Cohort Studies

KW - Female

KW - Gene Expression Regulation/genetics

KW - Humans

KW - Male

KW - Parkinson Disease/cerebrospinal fluid

KW - Parkinsonian Disorders/blood

U2 - 10.1002/mds.27542

DO - 10.1002/mds.27542

M3 - Journal article

C2 - 30557454

VL - 34

SP - 246

EP - 254

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 2

ER -

ID: 234449640